Galenicum Health Peru launches its first OTC product
March 22, 2018
In March 2018, Galenicum Health Peru is launching its first OTC product, Dormidina® (licensed by Esteve), indicated for the symptomatic treatment of occasional insomnia in people over 18 years of age.
Dormidina® is a leader in the insomnia market in Spain, following 25 years of continuous growth.
Dormidina® is the first product in the Peruvian market that contains doxylamine, which has been proven to be effective in inducing sleep after 30 minutes and increasing the depth and duration of sleep (between 6 and 8 hours).
Dormidina® will complement our prescription product portfolio, in which the main therapeutic areas are the central nervous system, oncology and the cardiovascular system.
In addition, it will be the first of several OTC products in the Galenicum pipeline.
Ask your doctor or pharmacist before you start taking Dormidina®.